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Background: Dendritic cells (DCs) are professional antigen-presenting cells with the ability to
induce primary T-cell responses and are commonly produced by culturing monocytes in the
presence of IL-4 and GM-CSF for 5–7 days (Standard DC). Recently, Dauer and co-workers
presented a modified protocol for differentiation of human monocytes into mature DCs within 48
hours (Fast DC). Here we report a functional comparison of the two strategies for generation of
DCs from human monocytes with adaptions for large-scale clinical use.
Methods: The Elutra Cell Selection System was used to isolate monocytes after collection of
leukapheresis product. The enriched monocytes were cultured in gas permeable Teflon bags with
IL-4 and GM-CSF for 24 hours (Fast DC) or 5 days (Standard DC) to obtain immature DCs. The
cells were then transfected with mRNA from the leukemia cell line Jurkat E6 by electroporation
and incubated for additional 24 h or 2 days in the presence of pro-inflammatory cytokines (TNFα,
IL-1β, IL-6 and PGE2) to obtain mature DCs.
Results:  M a t u r e  F a s t  D C  a n d  S t a n d a r d  D C  d i s p l a y e d  c o m p a r a b l e  l e v e l s  o f  m a n y  m a r k e r s
expressed on DC, including HLA-DR, CD83, CD86, CD208 and CCR7. However, compared to
Standard DC, mature Fast DC was CD14high CD209low. Fast DC and Standard DC transfected with
Jurkat E6-cell mRNA were equally able to elicit T cell specifically recognizing transfected DCs in
vitro. IFNγ-secreting T cells were observed in both the CD4+ and CD8+ subsets.
Conclusion: Our results indicate that mature Fast DC are functional antigen presenting cells
(APCs) capable of inducing primary T-cell responses, and suggest that these cells may be valuable
for generation of anti-tumor vaccines.
Background
Dendritic cells (DCs) are potent antigen-presenting cells
(APCs) involved in the induction of T-cell-mediated
immune responses and have appeared as important can-
didates for cellular-based therapies [1]. Immature DCs are
found throughout the body where they capture and proc-
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ess antigens (Ag). When activated by danger signals the
DCs start differentiation towards a mature penotype and
migration to the T cell dependent areas of secondary lym-
phoid organs. During this process, they lose the capacity
for Ag-capturing and upregulate major histocompatibility
complex (MHC)- and costimulatory molecules for stimu-
lation of naive T cells [2-4].
In vitro, DCs can be differentiated from various cellular
sources, including CD34+ progenitor cells from bone
marrow (BM) and cord blood (CB), and monocytes
obtained from peripheral blood mononuclear cells
(PBMCs) [5]. For clinical DC vaccines, monocytes have
been the general source for DC generation [6]. Monocyte-
derived DCs can be generated from PBMCs collected by
leukapheresis. Different monocyte enrichment tech-
niques are available including plastic adherence, immu-
nomagnetic separation as well as elutriation. By using the
Elutra® Cell Separation System (Gambro BCT), up to 20 ×
109 PBMCs can be elutriated within one hour, which
makes this device convenient for large scale isolation of
monocytes for further generation of DCs for clinical pur-
poses. Immature DCs can be generated from monocytes
by culturing for 5 days in serum-free medium containing
IL-4 and GM-CSF [7,8], and further matured using pro-
inflammatory cytokines as described previously [9].
Dauer and co-workers have developed a protocol for the
generation of DCs from human monocytes within 48
hours (Fast DC) [10,11]. Novel culture systems aimed to
reduce processing time for generation of DCs are likely to
become important for large-scale clinical production of
DCs. The aim of the present study was to investigate if this
protocol could be adapted for large-scale clinical use
involving collection of PBMCs by leukapheresis, isolation
of monocytes by using the Elutra™ Cell Separation Sys-
tem, and culturing in sterile Teflon bags. Using such a set-
up, we have compared DCs generated by the Fast DC and
standard protocols with respect to transfection efficiency,
DC phenotype, and T cell stimulatory capacity following
transfection with whole tumor mRNA.
Methods
Collection of peripheral blood mononuclear cells
PBMCs were collected by leukapheresis from patients with
advanced prostate cancer included in clinical trials of DC
vaccines [12] using Cobe Spectra (Gambro BCT). The
experiments were approved by the Regional Committee
for Medical Research Ethics and performed in compliance
with the World Medical Association Declaration of Hel-
sinki. Written informed consent was obtained from all
patients.
Isolation and culture of enriched monocytes in sterile 
VueLifeTM FEP Teflon bags
Monocytes were purified from PBMCs using the Elutra™
Cell Separation System (Gambro BCT). This is a semi-
automatic, centrifuge-based method using continuous
counter-flow elutriation technology to separate cells into
multiple fractions based on size and density. This proce-
dure resulted in a recovery of 75–90% of all monocytes
with a purity of 65–77% of CD14 positive cells. Between
0.9–1.3 × 109 monocytes were isolated and cultured at a
final concentration of 106cells/ml in Teflon bags with
serum-free CellGro DC medium supplemented with 2500
U/ml of GM-CSF and 1000 U/ml of IL-4 (CellGenix). The
cells were collected after 24 hours (Fast DC) or 5 days
(Standard DC) and transfected with mRNA isolated from
the leukemia cell line Jurkat E6 as described previously
[9]. After removal of samples for flowcytometry and con-
tamination test, the cells were incubated for additional 24
hours for FastDCs and 48 hours for Standard DC in Cell-
Gro DC medium supplemented with a maturation cock-
tail of proinflammatory cytokines:10 ng/ml IL-1α; 1000
U/ml IL-6; 10 ng/ml TNF-α (CellGenix) and 10 ng/ml
PGE2 (Sigma Aldrich). A fraction of the cells was cryopre-
served as described previously [13].
Cell lines
The leukemia cell line Jurkat E6 was obtained from the
American Type Culture Collection (ATCC). The cell line
was cultured in RPMI 1640 medium, supplemented with
penicillin (100 U/mL), streptomycin (100 μg/mL) and
10% fetal calf serum (FCS) (all from Sigma Aldrich). Cells
were maintained at 37°C in a humidified atmosphere
supplemented with 5% CO2.
Preparation of mRNA from Jurkat E6 cells
Total RNA was isolated from 25 × 106 Jurkat E6 cells using
Trizol Reagent (Invitrogen, Basel, Switzerland). Poly (A) +
mRNA was isolated from total RNA using the GenoPrep
Direct mRNA kit (GenoVision, Oslo, Norway). mRNA was
either used fresh or stored at -70°C until use.
Transfection of immature DCs with mRNA
Immature DCs were collected from the Teflon bags,
washed twice, and resuspended in 0.6–0.8 ml cold culture
DC medium and placed in a 4°C cooling block. mRNA
transfection was performed by electroporation as
described earlier [9]. To measure transfection efficiency,
cells were electroporated with EGFP-pCIpA102 mRNA
[14] encoding the enhanced green fluorescence protein
and analysed by flow cytometry (FACSCalibur, Becton
Dickinson). Cells electroporated without mRNA (mock
DCs) were used as negative control.BMC Cancer 2007, 7:119 http://www.biomedcentral.com/1471-2407/7/119
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Flowcytometry measurements
Immature and mature DCs were phenotyped using a four-
color panel of monoclonal antibodies: CD14 APC, Anti-
HLA-DR PerCp, CD86 FITC (all BD Bioscience, San Jose,
C A ) ,  C D 1 a  F I T C  ( D A K O  A / S ,  D e n m a r k ) ,  C D 8 3  P E ,
CD209 PE, CD208 PE (Immunotech, France) and CCR7
APC (R&D Systems). Isotype-matched antibodies were
used for negative controls. Cells were analyzed using the
FACSCalibur flow cytometer and CellQuest software (BD
Biosciences).
Test for in vitro stability of mature phenotype (Washout 
test)
Fully mature DCs are capable of retaining their phenotype
following culture in DC medium without any cytokines.
Frozen mature DCs were thawed and cultured in DC
medium alone. After 24 and 48 hours in culture the DCs
phenotype was analyzed using Flow Cytometry. The qual-
ity control of the frozen-produced DCs consisted of steril-
ity tests, phenotyping and viability testing by trypan blue
staining before freezing and after thawing.
Generation of T-cell responses in vitro
Thawed autologous PBMCs were plated in 6-well plates,
20 × 106 cells in 3 ml of DC medium per well, and incu-
bated for 2 hours at 37°C in 5% CO2. Non-adherent T
lymphocytes were collected and used as responder cells: 3
× 106 cells in 1 ml of DC medium supplemented with
antibiotic. Thawed mRNA-transfected DCs used as stimu-
lator cells were washed once and irradiated with 300 Gy.
After washing, the cells were resuspended in DC medium
at a final concentration of 0.3 × 106 cells/ml. To each well
containing responder cells, 1 ml of the prepared DCs was
added. The Negative Isolation Kit from (Dynal, Biotech)
was used for isolation of CD4 and CD8 T cells according
to the manufacturer's protocol. Isolation was performed
on day 7 after in vitro priming and ELISPOT assay was per-
formed essentially as described earlier [9]. Briefly, 7 day
primed T cells (50–400.000 cells per well) were tested
with 5000 mock transfected control DCs or the same
number of transfected DCs in plates coated with anti IFN-
gamma antibodies overnight in duplicate cultures. Spot
forming cells were counted manually the next day.
Results
Morphological comparison of Fast DC with Standard DC
The morphology of Fast DC was compared to Standard
DC by fluorescent microscopy of EGFP transfected DCs.
Fast DC in the mature stage were similar to monocytes in
size, but they developed cytoplasmic protrusions. In con-
trast, Standard DCs were larger in size and had long
motile cytoplasmic processes ('veils') typical of terminally
differentiated dendritic cells. Flow cytometric analysis
(Fig. 1) confirmed the fluorescent microscopy findings.
Immunophenotype of Fast and Standard DC
Phenotypic characteristics of Fast DC have previously
been reported by Dauer et al [10] for small scale labora-
tory production. In three parallel experiments, 200 × 106
monocytes were cultured for DC development and an
average of 98 × 106 immature DCs were obtained after 24
hours of incubation, resulting in a mean of 53 × 106
mature DCs after additional 24 hours in culture (26,5% of
initial monocytes seeded). The cell recovery and viability
of mature Fast DC and Standard DC were similar (results
not shown) [5]. The phenotypic analysis of mature Fast
DC showed that about 93–98% of cells had high levels of
HLA-DR. After 24 hours of maturation, Fast D showed up
regulation of CD83 and CD86 (Fig. 1). Fast DC expressed
significantly lower amounts of CD1a and CD209 than
Standard DC. About 30% of the Fast DC expressed the
monocyte marker CD14, indicating that 48 hrs was not
sufficient for complete down-regulation of this monocyte
marker.
Stability of immunophenotype
To investigate if the Fast DC had gained a stable pheno-
type during the short differentiation period the cells were
frozen and thawed and incubated without exogenously
added cytokines for 48 hrs. The results show that a stable
phenotype of the DCs was obtained for both cell types
(Fig 2a–b). One exception was CD14, which seemed to
some extent to re-appear on Standard DC and not dimin-
ish further on Fast DC. Interestingly, incubation of Fast
DC under cytokine-free conditions led to increased
expression of CCR7 over time (Fig. 2b), similar to the lev-
els seen in Standard DC.
Efficiency of mRNA transfection in different types of DCs
Electroporation with EGFP mRNA was performed after 5
days in culture for Standard DC, and after 24 hours for
Fast DC. The electroporation was performed at 500 volt
for 1 millisecond in a 4-mm cuvette using the BTX ECM-
830 square-wave electroporator (Genetronics Inc., San
Diego, CA). The viability of transfected Fast DC and
Standard DC was similar to non-transfected cells, and the
transfection rate was close to 100% (Fig. 3). The average
green fluorescence in EGFP-mRNA transfected DCs was
2.7 times higher in Standard DC compared to mature Fast
DC, probably reflecting the difference in size (Fig. 3).
T-cell stimulatory capacity of FastDCs and Standard DC
Tumour mRNA-loaded FastDCs and Standard DC were
co-cultured with autologous T cells in serum free DC
medium, without addition of cytokines. After 7 days, IFN-
γ production from autologous T cells co-cultured with
mRNA transfected Fast DC or Standard DC were analyzed
in an ELISPOT assay (Fig. 4). T cells primed for one week
with thawed antigen-loaded DCs demonstrated a specific
T-cell response against mRNA-loaded DCs compared toBMC Cancer 2007, 7:119 http://www.biomedcentral.com/1471-2407/7/119
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mock DCs. This was observed for both Fast DCs and
Standard DC. The total number of spot-forming cells was
proportional to the number of T cells added to the wells.
This was also seen with mock transfected DCs. Priming
with Fast DC in general produced more IFN-γ-secreting T
cells compared to Standard DC, both with mRNA- and
mock-transfected DCs, resulting in a higher background.
When considering the differences in the number of IFN-γ-
secreting T cells between mRNA- and mock-transfected
DCs, Fast DC and Standard DC appeared to be equally
efficient in producing specific T-cell responses against the
mRNA encoded antigens. To address which of the T-cell
subpopulations were responsible for the IFN-γ secretion
in the ELISPOT assay, CD4+ and CD8+ T cells were iso-
lated using negative selection with Dynabeads coated with
CD8 and CD4 antibodies respectively and analysed in
separate assays. The results (Fig. 4) demonstrate that both
CD4+ and CD8+ responses were obtained in all patients.
While Standard DC activated comparable numbers of
CD4+ and CD8+ T cells, the T cell response against Fast
DC seemed to be dominated by CD4+ T cells.
Discussion
Our experiments demonstrate that mature Fast DC can be
generated from monocytes within 48 hours in a large-
scale clinical setting. Furthermore our results indicate that
Comparative phenotypic analysis of Standard DC and mature FastDCs by flow cytometry Figure 1
Comparative phenotypic analysis of Standard DC and mature FastDCs by flow cytometry. Surface expression of a panel of anti-
gens was determined following maturation with TNFα, IL1β, IL6 and PgE2 for 24 hours (mature FastDCs) and 48 hours (Stand-
ard DC). Open diagram shows reactivity with control mAbs. Closed diagrams shows reactivity with anti HLA-DR and CD 
antibodies. The setting of the gates based on the forward (FSC) and site scatter (SSC) is indicated to the left in the figure. One 
representative of three performed experiments is presented.
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priming of a T cell response by Fast DC and Standard DC
following tumour mRNA loading is equally efficient, indi-
cating that Fast DC may substitute for conventional DCs
in clinical trials. Some differences between mature Fast
DC and conventional monocyte derived DCs were noted.
Compared to Standard DCs, Fast DC displayed a mixed
phenotype (CD83+, CD208+, CD86+) with some expres-
sion of CD14 retained. After analyzing the phenotype of
DC maintained in the washout cultures for up to 48 h we
observed CD14 re-appear on Standard DC and not dimin-
ish further on Fast DC. This results confirmed previous
findings, indicating that monocyte-derived DCs stimu-
lated with proinflammatory cytokines may not be termi-
nally differentiated cells [15]. A significant difference
between the results reported here and those reported in
[10] is the level of CD14 remaining on immature and
mature Fast DC. Whereas Dauer et al [10] used positive
selection of monocytes by the MACS CD14 isolation kit to
obtain monocytes, we used elutriation. Moreover, the two
methods also differed in the use of media, sera, GM-CSF
concentration and type of culture vessel. We believe that
the difference may result from the use of magnetic parti-
Phenotypical stability of mature dendritic cells, Standard DC (a) and Fast DC (b), after freezing/thawing and incubation without  cytokines Figure 2
Phenotypical stability of mature dendritic cells, Standard DC (a) and Fast DC (b), after freezing/thawing and incubation without 
cytokines. Dotted line, isotype-matched control; blue line, before freezing/thawing; green line, 24 hrs in culture without 
cytokines; red line, 48 hrs in culture without cytokines. One of three performed experiments is presented.BMC Cancer 2007, 7:119 http://www.biomedcentral.com/1471-2407/7/119
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mRNA transfection of DCs Figure 3
mRNA transfection of DCs. Flow cytometric analysis of mature FastDCs and Standard DC after transfection with EGFP/
pCIpA102 mRNA (10 μg/400 μl) by square-wave electroporation and maturation for 24 hours in medium with maturation cock-
tail. Control cells were incubated on ice with EGFP mRNA without electrophoresis, washed and incubated for 24 hrs. Condi-
tions for electroporation were 500 volt and 1-ms when using a 4-mm-gap cuvette.
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cles conjugated with CD14 antibodies in the Dauer proto-
col. The fact that CD14 is bound by the antibodies on the
particles and thus internalized by the monocytes during
subsequent culture may explain the complete loss of
CD14 during the in vitro culture with DC differentiating
cytokines in their protocol. CD1a was significantly lower
expressed in Fast DC than in Standard DC, while other
markers such as CD83, CD208 and CCR7 were expressed
on a similar proportion of both cell types. The lower
expression of CD1a is probably not of any functional
importance in the context of mRNA loaded DC to be used
as cancer vaccines, since this molecule functions to
present bacterial lipids to T cells. Expression of CD209
was low in mature Fast DC and was lost almost com-
pletely upon incubation of the cells in the absence of
cytokines. CD209 or DC-SIGN (Dendritic cell-specific
ICAM-3 grabbing nonintegrin) plays important roles in
macrophage and DC recognition of pathogens but seem
not to be required for T cell activation [16]. CD209 thus
probably exerts its main role in antigen uptake and
processing, rather than in the phase were antigen is pre-
sented to the T cells. In mature Fast DC the expression of
CCR7 increased over time (after 24 hours and 48 hours),
to some extent this was also the case in the Standard DC.
The chemokine receptor CCR7 is a key molecule for the
entry of lymphocytes and dendritic cells into secondary
lymphoid organs and their homing to T cell and B cell
zones. Although Fast DC were morphologically smaller
and with less surface membrane protrusions, overall, the
data on the phenotype of mature Fast DC indicates that
these cells compare favorably with conventional DCs and
supports the suggestion that such cells may be ready for
clinical trials.
In our approach to clinical studies [12,17], the ability of
DCs transfected with mRNA isolated from tumor cell line
or tissue to induce T cell responses is important. Immature
Fast DC was readily transfected with mRNA encoding
EGFP. More importantly, when immature Fast DC were
transfected with mRNA isolated from Jurkat E6 leukemia
cell line, which was used as a tumor model, T cells specific
for transfected DCs were readily picked up in the IFNγ
ELISPOT assay after one single cycle of in vitro stimula-
tion of autologous T cells. Both CD4+ and CD8 + T cells
ELISPOT analysis of T-cell activation Figure 4
ELISPOT analysis of T-cell activation. T cells were stimulated with DCs transfected with tumor mRNA or control DCs (mock 
transfected) as indicated. Mean number of IFN γ positive spots from duplicate wells obtained with the indicated numbers of un-
fractionated T cells, and CD4+ and CD8+ T-cell subsets from individual patients. Results are presented as mean +/- standard 
deviation (SD).
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were evident. Due to a prominent autologous mixed leu-
kocyte reaction (MLR) seen when DCs are co-incubated
with autologous T cells, background reactivity is often a
problem in the immuno monitoring assays. The same
phenomenon is observed in patients vaccinated with DCs
and auto-MLR reactive T cells from DC-vaccinated
patients can be characterized at the clonal level. [18-20].
This seems also to be the case when mature Fast DC are
used.
Production of Standard DC under GMP conditions for
clinical use is time, cost and labor intensive and represents
a bottleneck in personalized vaccine development. Dauer
et al [10] recently reported that mature Fast DC could be
obtained following the same conditions as for Standard
DC with phenotypic characteristics as well as functional
properties similar to DCs generated by the standard pro-
tocol. We have adapted the method of Dauer to full-scale
GMP production of Fast DC required for clinical trials.
Compared with common standard 7-days protocol, this
new strategy simplified the process and reduced labor,
cost and time for the whole experimental procedure. In
the clinical setting this may provide an opportunity to
treat more patients in a shorter period of time. Based on
previous pre-clinical experiments [9,17,5], we are cur-
rently engaged in clinical trials using mRNA transfected
Standard DC as cancer vaccines [12].
Conclusion
The present experiments using full-scale production dem-
onstrate that adequate numbers of mature and functional
Fast DC for clinical vaccines can be obtained in a repro-
ducible manner from patients with advanced cancer and
paves the way for implementing this method in our clini-
cal trials.
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